Strides Shasun today said it has received an approval from the US health regulator for Ranitidine tablets used for treating intestinal and stomach ulcers and gastroesophageal reflux disease.
In a BSE filing, Strides Shasun said "it has received approval from the US Food and Drug Administration (USFDA) for Ranitidine tablets USP, 150 mg and 300 mg".
The company will manufacture the product at its Cuddalore and Pondicherry facilities.
According to IMS sales data, the US market for Ranitidine tablets USP, 150 mg and 300 mg is around USD 125 million.
Strides Shasun's shares were trading 1.35 percent higher at Rs 970.50 apiece on BSE.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
